These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

140 related articles for article (PubMed ID: 36458618)

  • 21. Analysis of terms used for the diagnosis and classification of amyotrophic lateral sclerosis and motor neuron disease.
    Rutter-Locher Z; Turner MR; Leigh PN; Al-Chalabi A
    Amyotroph Lateral Scler Frontotemporal Degener; 2016; 17(7-8):600-604. PubMed ID: 27188215
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Risk of amyotrophic lateral sclerosis and other motor neuron disease among men with benign prostatic hyperplasia: a population-based cohort study.
    Sørensen TT; Horváth-Puhó E; Nørgaard M; Ehrenstein V; Henderson VW
    BMJ Open; 2019 Jul; 9(7):e030015. PubMed ID: 31278107
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Younger age of onset in familial amyotrophic lateral sclerosis is a result of pathogenic gene variants, rather than ascertainment bias.
    Mehta PR; Jones AR; Opie-Martin S; Shatunov A; Iacoangeli A; Al Khleifat A; Smith BN; Topp S; Morrison KE; Shaw PJ; Shaw CE; Morgan S; Pittman A; Al-Chalabi A
    J Neurol Neurosurg Psychiatry; 2019 Mar; 90(3):268-271. PubMed ID: 30270202
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Validating population-based registers for ALS: how accurate is death certification?
    Yeo L; Lynch C; Hardiman O
    J Neurol; 2010 Aug; 257(8):1235-9. PubMed ID: 20151145
    [TBL] [Abstract][Full Text] [Related]  

  • 25. An MND/ALS phenotype associated with C9orf72 repeat expansion: abundant p62-positive, TDP-43-negative inclusions in cerebral cortex, hippocampus and cerebellum but without associated cognitive decline.
    Troakes C; Maekawa S; Wijesekera L; Rogelj B; Siklós L; Bell C; Smith B; Newhouse S; Vance C; Johnson L; Hortobágyi T; Shatunov A; Al-Chalabi A; Leigh N; Shaw CE; King A; Al-Sarraj S
    Neuropathology; 2012 Oct; 32(5):505-14. PubMed ID: 22181065
    [TBL] [Abstract][Full Text] [Related]  

  • 26. [Phenotypes in ALS--clinical features and pathology].
    Sasaki S
    Brain Nerve; 2007 Oct; 59(10):1013-21. PubMed ID: 17969341
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Patients with Amyotrophic Lateral Sclerosis Have High Interest in and Limited Access to Genetic Testing.
    Wagner KN; Nagaraja H; Allain DC; Quick A; Kolb S; Roggenbuck J
    J Genet Couns; 2017 Jun; 26(3):604-611. PubMed ID: 27761850
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Identifying who will benefit from non-invasive ventilation in amyotrophic lateral sclerosis/motor neurone disease in a clinical cohort.
    Berlowitz DJ; Howard ME; Fiore JF; Vander Hoorn S; O'Donoghue FJ; Westlake J; Smith A; Beer F; Mathers S; Talman P
    J Neurol Neurosurg Psychiatry; 2016 Mar; 87(3):280-6. PubMed ID: 25857659
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Genetic counselling and testing for neurodegenerative disorders using a proposed standard of practice for ALS/MND: diagnostic testing comes first.
    Crook A; McEwen A
    Eur J Hum Genet; 2022 Apr; 30(4):394-395. PubMed ID: 34983943
    [No Abstract]   [Full Text] [Related]  

  • 30. The future of motor neuron disease: the challenge is in the genes.
    Veldink JH; Van den Berg LH; Wokke JH
    J Neurol; 2004 Apr; 251(4):491-500. PubMed ID: 15083302
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Aggregation of neurologic and neuropsychiatric disease in amyotrophic lateral sclerosis kindreds: a population-based case-control cohort study of familial and sporadic amyotrophic lateral sclerosis.
    Byrne S; Heverin M; Elamin M; Bede P; Lynch C; Kenna K; MacLaughlin R; Walsh C; Al Chalabi A; Hardiman O
    Ann Neurol; 2013 Nov; 74(5):699-708. PubMed ID: 23836460
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Assisted ventilation in motor neurone disease during inpatient palliative care: barriers and utilisation.
    Gleeson A; Johnson F
    BMJ Support Palliat Care; 2020 Sep; 10(3):358-362. PubMed ID: 30712020
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Value of systematic genetic screening of patients with amyotrophic lateral sclerosis.
    Shepheard SR; Parker MD; Cooper-Knock J; Verber NS; Tuddenham L; Heath P; Beauchamp N; Place E; Sollars ESA; Turner MR; Malaspina A; Fratta P; Hewamadduma C; Jenkins TM; McDermott CJ; Wang D; Kirby J; Shaw PJ; ;
    J Neurol Neurosurg Psychiatry; 2021 May; 92(5):510-518. PubMed ID: 33589474
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Toward genetic counseling practice standards for diagnostic testing in amyotrophic lateral sclerosis and frontotemporal dementia.
    Crook A; Jacobs C; Newton-John T; McEwen A
    Amyotroph Lateral Scler Frontotemporal Degener; 2022 Nov; 23(7-8):562-574. PubMed ID: 35343344
    [No Abstract]   [Full Text] [Related]  

  • 35. A randomised controlled trial of acceptance and commitment therapy plus usual care compared to usual care alone for improving psychological health in people with motor neuron disease (COMMEND): study protocol.
    Gould RL; Thompson BJ; Rawlinson C; Kumar P; White D; Serfaty MA; Graham CD; McCracken LM; Bursnall M; Bradburn M; Young T; Howard RJ; Al-Chalabi A; Goldstein LH; Lawrence V; Cooper C; Shaw PJ; McDermott CJ
    BMC Neurol; 2022 Nov; 22(1):431. PubMed ID: 36380299
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Spirituality and/or religious faith: A means for coping with the effects of amyotrophic lateral sclerosis/motor neuron disease?
    O'Brien MR; Clark D
    Palliat Support Care; 2015 Dec; 13(6):1603-14. PubMed ID: 25851240
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Chromosome 9p21 in sporadic amyotrophic lateral sclerosis in the UK and seven other countries: a genome-wide association study.
    Shatunov A; Mok K; Newhouse S; Weale ME; Smith B; Vance C; Johnson L; Veldink JH; van Es MA; van den Berg LH; Robberecht W; Van Damme P; Hardiman O; Farmer AE; Lewis CM; Butler AW; Abel O; Andersen PM; Fogh I; Silani V; Chiò A; Traynor BJ; Melki J; Meininger V; Landers JE; McGuffin P; Glass JD; Pall H; Leigh PN; Hardy J; Brown RH; Powell JF; Orrell RW; Morrison KE; Shaw PJ; Shaw CE; Al-Chalabi A
    Lancet Neurol; 2010 Oct; 9(10):986-94. PubMed ID: 20801717
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Genetic testing in motor neurone disease.
    Dharmadasa T; Scaber J; Edmond E; Marsden R; Thompson A; Talbot K; Turner MR
    Pract Neurol; 2022 Apr; 22(2):107-116. PubMed ID: 35027459
    [TBL] [Abstract][Full Text] [Related]  

  • 39. "Switchboard" malfunction in motor neuron diseases: Selective pathology of thalamic nuclei in amyotrophic lateral sclerosis and primary lateral sclerosis.
    Chipika RH; Finegan E; Li Hi Shing S; McKenna MC; Christidi F; Chang KM; Doherty MA; Hengeveld JC; Vajda A; Pender N; Hutchinson S; Donaghy C; McLaughlin RL; Hardiman O; Bede P
    Neuroimage Clin; 2020; 27():102300. PubMed ID: 32554322
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Transcriptomic profiling of cerebrospinal fluid identifies ALS pathway enrichment and RNA biomarkers in MND individuals.
    Fröhlich A; Pfaff AL; Bubb VJ; Quinn JP; Koks S
    Exp Biol Med (Maywood); 2023 Dec; 248(23):2325-2331. PubMed ID: 38001563
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.